After proof of efficacy in patients with melanoma in a clinical trial, major efforts are now directed to make the use of TILs easier and safer in clinical practice.

Novel targeted strategies are investigated in uveal melanoma, especially for those who do not respond to the bispecific fusion protein, with some encouraging early-phase data from c-MET/PKC inhibitors

Antitumour responses were consistent with those previously reported for a broader population of patients with advanced melanoma 

Regulatory, practical and economic challenges are associated with implementing this personalised treatment on a larger scale, thus currently limiting its availability and accessibility to patients

In a head-to-head comparison to the standard of care, tumour-infiltrating lymphocytes show clinical efficacy even in patients who are refractory to anti-PD-1 treatment 

Since its approval, tebentafusp is changing the treatment landscape for patients with metastatic uveal melanoma, but many questions remain

However, according to the winner of the ESMO Award for Translational Research 2022, Dr Samra Turajlic, results will only be achieved through a collaborative effort of the oncology community

Data from SECOMBIT provide useful insights to the optimal sequence of immune checkpoint inhibitor therapy and targeted treatment combinations for patients with BRAF-mutated, advanced melanoma 

Studies also suggest hope for TKI inhibitor combinations in patients with symptomatic brain metastases

Immunotherapy was associated with a significant reduction in the risk of disease recurrence compared with placebo in patients with melanoma